Metastatic castration-resistant prostate cancer – New learnings and perspectives
2020-07-24
Prof. de Wit (NL) gave a summary of the CARD study: a randomized, open-label study of cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer.
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.I agreeRead More